Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

BioCryst Pharmaceuticals

Gilead Sciences

Inovio Pharmaceuticals

Moderna

These five biotechs are likely to remain on the volatile side this week, thanks to the novel-coronavirus threat.

Could These 5 Stocks Benefit From the Coronavirus Outbreak?

Johnson & Johnson

Healthcare giant J&J and small biotech Novavax are both scrambling to develop coronavirus drugs. Which stock is the better pick?

Better Coronavirus Play: Johnson & Johnson vs. Novavax

Regeneron Pharmaceuticals

Vir Biotechnology

Some biotech firms have been outperforming the market over the past few weeks on their treatment initiatives.

Investors rush into biotechs working on coronavirus vaccine

Aethlon Medical

NanoViricides

The story that has dominated this past week is that China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.

Biotech Stocks Seeing the Biggest Boost From Coronavirus Outbreak

Sarepta Therapeutics

China is facing an outbreak of the coronavirus, and more countries around the world are seeing cases pop up.

Coronavirus Infections Climb Hand in Hand With These Biotech Stocks

Nordic American Tankers

Virgin Galactic

Right now you can buy an interstellar airline, a vaccine specialist, and an oil tanker company -- all on sale.

3  Top  Stocks  Under  $20

Two stocks fell, while one popped, as investors speculate over the potential financial impact from the Wuhan coronavirus outbreak. (Hint: it's unlikely to move the needle.

Here's Why These Small-Cap Pharma Stocks Are Volatile Today

Increased fears about a viral outbreak are causing the biotech stock to rise even more after last week's big gains.

Why Novavax Shares Are Jumping Again Today

Allied Healthcare Products

Alpha Pro Tech

Cerus

Co-Diagnostics

Dyadic International Inc., DE

Lakeland Industries

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

12 Stocks Surging That Could Help Treat or Fight Coronavirus

Shares of a handful of vaccine makers, diagnostics companies and manufacturers of medical supplies, like masks, rallied again in premarket trading on Monday over growing public concern about the new coronavirus. This includes Co-Diagnostics Inc.

Vaccine, diagnostics stocks rise again on spreading coronavirus

Investors are bidding up these biotechs in response to the health threat.

2 Stocks That Could Skyrocket Over the Chinese Coronavirus Threat

But it's important to separate the current panic from the real potential for these biotechs.

5 Biotech Stocks to Watch With the Coronavirus Scare

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.

CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

The vaccine maker's stock is getting a lift from a pair of catalysts this morning.

Why Novavax Shares Are Jumping Today  (NVAX)

Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.

3 Biotech Stocks Likely to Gain as Coronavirus Spreads

AstraZeneca

Cleveland BioLabs

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

SPDR S&P Biotech ETF

Shares of vaccine makers rose sharply again on Thursday, amid rising concerns about the outbreak of a new coronavirus in Wuhan, China that has led the authorities to quarantine the city of 11 million.

Vaccine stocks rise sharply as coronavirus fears mounts

Yesterday's euphoria that a virus scare could boost the biotech's fortunes has given way to a more realistic assessment of what's going on.

Why Novavax Shares Are Sinking Today

The outbreak of a deadly respiratory virus caused Novavax's shares to take flight yesterday. Can the biotech's stock climb even higher, or is it time to take profits?

Up 71%, Is Novavax Stock Still a Strong Buy?

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Novavax (NVAX) Stock

Shares of Novavax Inc. NVAX, +71.08% tumbled 15% in premarket trading on Wednesday following a day in which growing concern about the new coronavirus sent shares of vaccine developers soaring.

Novavax stock falls after jumping on virus concerns

Oncolytics Biotech, Inc.

While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.

Coronavirus Infects Wall Street: Stocks to Gain & Lose

Vaccine-maker Novavax is running up on the news the coronavirus has infected a person in Washington state.

Wuhan Coronavirus Hits the U.S. And Vaccine Stock Soars

Novavax, Inc. (NASDAQ: NVAX) said Tuesday afternoon it has initiated development of a vaccine candidate for the Wuhan-version of the coronavirus that has spread from China to other Asian nations and on Tuesday was confirmed to have infected at least one person in the United States.

Novavax Is Working On A Wuhan Coronavirus Vaccine Candidate As First US Case Emerges

Novavax (NVAX) news for Tuesday concerning the spread of a virus in China has NVAX stock heading higher as more investors pick up the stock.
The post Novavax News: NVAX Stock Skyrockets 52% on Mystery China Virus appeared first on InvestorPlace.

News for Novavax Stock (NVAX)